On May 21, 2018, the executive team of Merus lead by Dr. Ton Logtenberg, CEO of Merus visited the headquarter of Simcere.
This is the first time this European biotech visit Simcere since the two parties announced collaboration on the development and commercialization in China three bispecific antibodies utilizing Merus’proprietary Biclonics® technology platform in the area of immuno-oncology.
During meeting with Simcere’s Chairman Mr Jinsheng Ren and Simcere’s scientists team, both companies exchanged information on the recent development and discussed possibility for future collaboration. They also took a tour to Simcere’s biological R&D platform.
Dr. Logtenberg commented that besides the beautiful campus, he was also impressed with the wisdom and capability of Simcere scientist during this visit.